Back from the dead: TIL apoptosis in cancer immune evasion.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Macrophage-derived Fgl2 dampens antitumor immunity through regulation of FcγRIIB+CD8+ T cells in melanoma.JCI insight · 2025
   Article
2. Adhesion analysis via a tumor vasculature-like microfluidic device identifies CD8Cell reports · 2023
   Article
3. Multilevel mechanism of immune checkpoint inhibitor action in solid tumors: History, present issues and future development.Oncology letters · 2022
   Review
4. Programmed Cell Death Tunes Tumor Immunity.Frontiers in immunology · 2022
   Review
5. Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy.JCI insight · 2018
   Article

Corrections and comments

• Comment on
  Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.2017
• Comment on
  Intratumoral CD82018

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as